HOME

TaiRx US, Inc. is an R&D based pharmaceutical company committed to developing novel therapeutics and precision medicine diagnostics for cancer treatment.

TaiRx US, Inc. is a subsidiary of TaiRx, Inc., a publicly-traded pharmaceutical company headquartered in Taipei, Taiwan.

TaiRx US, Inc. is an independent, Delaware C-Corp that has exclusive, worldwide rights to the patent estate on Nodal established by Mary J. C. Hendrix, Ph.D., the former President of the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine, and now President of Shepherd University, who led the research delineating the critical role Nodal plays in cancer. Nodal, a secreted growth-promoting protein that is normally and predominantly expressed in the embryo — was discovered to be re-expressed in cancer cells during progression and metastasis and associated with resistance to known therapies.

Our team has extensive experience and knowledge in new drug development. This allows us to expedite the drug development process of our identified drug candidates going from early development to regulatory IND/NDA approval.